The latest news about Samsung Bioepis
18:00 ON JUN 30, 2020 KST
INCHEON, Korea – June 30, 2020 – Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB15, the company's proposed biosimilar referencing Eylea® (aflibercept). The Phase 3 clinical trial for SB15 (aflibercept) is a randomised, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB15 and Eylea® in 446 patients with neovascular age-related macular degeneration. For more information, please visit clinicaltrials.gov (NCT #04450329).
Samsung Bioepis has two ophthalmology biosimilar candidates in clinical development, SB11 (ranibizumab) and SB15 (aflibercept). The company has recently announced 24-week interim results from a Phase 3 clinical trial for SB11.
# # #
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media– Twitter, LinkedIn.
Evelyn Hong: +82-31-8061-1215, email@example.com
Anna Nayun Kim: +82-31-8061-1604, firstname.lastname@example.org
Yoon Kim: +82-31-8061-1783, email@example.com
i Eylea® is a registered trademark of Regeneron Pharmaceuticals